WHO Begins Bundibugyo Ebola Treatment Trial in DR Congo

The World Health Organization began a clinical trial of two antiviral treatments for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo on Thursday ^[5].

This trial is critical because the Bundibugyo strain of the virus continues to spread across the region, necessitating a verified medical intervention to reduce mortality rates and halt the transmission of the disease.

The trial focuses on the safety and efficacy of two specific antiviral therapies: MBP134 and remdesivir [2, 6]. These treatments are being tested in the Bunia region of the Ituri province [3, 4]. The WHO coordinated the effort to determine if these drugs can effectively control the virus in patients during the current outbreak.

Health officials are racing to contain the virus as the scale of the crisis grows. Reported cases in the Democratic Republic of Congo have reached 1,427 ^[2], while death tolls are reported between 438 ^[3] and 440 ^[2]. The discrepancy in numbers reflects the challenges of tracking cases in the affected provinces.

The trial officially commenced on July 2, 2026, with the enrollment of its first patient ^[5]. By testing multiple therapies simultaneously, the WHO aims to identify the most effective protocol for treating the Bundibugyo strain, which may differ in response to medication compared to other Ebola variants.

Medical teams in the Ituri province are managing the administration of the drugs and monitoring patient outcomes. The results from this trial will inform future public health responses and potentially provide a standardized treatment plan for future Ebola outbreaks in Central Africa.